One in six adults experiences major depressive disorder at some point in life. Global estimates reached 264 million cases in recent data. Prevalence stands at 8.3 percent for women and 5.3 percent for men, with the highest rates among adults aged 18 to 29.
Key Takeaways
- 1 in 6 adults (16.6%) experience MDD at some point in their lifetime
- 264.0 million people globally had depression in 2020 (estimates from the Global Burden of Disease)
- 5.8% of adults experience depressive symptoms in the United States (2018–2019 estimate)
- Depressive disorders are estimated to be most common among ages 18–29 years (global pattern in WHO/GBD-based summaries)
- Depression affects 8.3% of women and 5.3% of men globally (prevalence by sex in WHO fact sheet)
- In the U.S., depression prevalence is higher among adults with diabetes and among adults with coronary heart disease (NHIS/CDC fastats)
- Depression and anxiety disorders are among the leading causes of years lived with disability, increasing health system and societal costs (GBD burden framing)
- In the U.S., mental health services expenditures are a major component of national healthcare spending, with depression contributing substantially (CMS/NHEC category reporting context)
- In the U.S., 44.7% of adults with mental illness received treatment in 2021 (depression is commonly included among treated conditions)
- In the U.S., 62% of people with major depression received some form of treatment in the past year (2019 NSDUH)
- ECT is an effective treatment option for severe depression where rapid response is needed (NICE guidance)
- The global burden of depression ranks among the top causes of non-fatal health loss measured by years lived with disability (YLDs) in the Global Burden of Disease
- From 2007 to 2017, the global prevalence of depression increased by an estimated ~18% (trend estimate in IHME/GBD-based analyses)
- In 2021, the U.S. had one of the highest increases in depression-related symptom reporting compared with earlier prepandemic patterns in national surveys (CDC MMWR pandemic surveillance)
- 25.8% of adults with depression had a co-occurring anxiety disorder (U.S. National Comorbidity Survey Replication estimate for 12-month prevalence of comorbidity).
One in six adults worldwide experiences major depression, making it a leading cause of disability.
Related reading
01 · Category
Prevalence6 stats
01
1 in 6 adults (16.6%) experience MDD at some point in their lifetime
02
264.0 million people globally had depression in 2020 (estimates from the Global Burden of Disease)
03
5.8% of adults experience depressive symptoms in the United States (2018–2019 estimate)
04
13.2% of adults in the U.S. reported symptoms of depression (2019–2020 estimate)
05
At least 10.5% of U.S. adults (age 18+) had past-year major depressive episode (MDE) in 2018 (NSDUH-based estimate in SAMHSA report).
06
In the WHO World Mental Health Surveys, about 1 in 14 people (≈7.1%) report having a depressive disorder within the 12 months preceding interview (cross-national survey finding reported by Kessler et al.).
Interpretation
Prevalence Interpretation
From a prevalence perspective, major depression is far from rare, with about 1 in 6 adults (16.6%) experiencing it at some point in their lifetime and 5.8% to 13.2% reporting depressive symptoms in the United States over recent survey years.
02 · Category
Demographics & Risk11 stats
01
Depressive disorders are estimated to be most common among ages 18–29 years (global pattern in WHO/GBD-based summaries)
02
Depression affects 8.3% of women and 5.3% of men globally (prevalence by sex in WHO fact sheet)
03
In the U.S., depression prevalence is higher among adults with diabetes and among adults with coronary heart disease (NHIS/CDC fastats)
04
In the U.S., 16.5% of adults reporting depression are aged 18–44 (NHIS/NCHS demographic tabulations)
05
People with chronic conditions have higher depression prevalence; in NHIS-based estimates, depression prevalence increases with the number of chronic diseases
06
A meta-analysis reports a significant association between childhood adversity and adult depression, with childhood adversities increasing risk (pooled odds ratios reported)
07
Genetic factors contribute substantially to the risk of MDD; twin studies estimate heritability around 30–40% (review estimate)
08
A strong association exists between sleep problems and depression; meta-analytic evidence shows increased risk of depression among those with insomnia symptoms
09
Substance use disorder is associated with higher odds of depression; cohort/meta-analytic evidence reports elevated depressive symptoms among individuals with SUD
10
Loneliness and social isolation are associated with higher risk of depression; meta-analytic evidence reports a significant relationship
11
Gender identity minority status is associated with higher rates of depression symptoms in population surveys (U.S. national estimates from CDC/YRBSS-style analyses)
Interpretation
Demographics & Risk Interpretation
Major depression is most prevalent in young adults aged 18–29 and is more common in women than men worldwide at 8.3% versus 5.3%, while in the United States it also concentrates among people with chronic illness and diabetes and shows that 16.5% of adults reporting depression are aged 18–44, underscoring how demographics and health risks strongly shape who is most affected.
03 · Category
Access & Costs2 stats
01
Depression and anxiety disorders are among the leading causes of years lived with disability, increasing health system and societal costs (GBD burden framing)
02
In the U.S., mental health services expenditures are a major component of national healthcare spending, with depression contributing substantially (CMS/NHEC category reporting context)
Interpretation
Access & Costs Interpretation
Depression and anxiety disorders are among the leading causes of years lived with disability, driving rising health system and societal costs, and in the U.S. mental health services make up a major share of national healthcare spending with depression as a substantial contributor.
04 · Category
Treatment & Outcomes8 stats
01
In the U.S., 44.7% of adults with mental illness received treatment in 2021 (depression is commonly included among treated conditions)
02
In the U.S., 62% of people with major depression received some form of treatment in the past year (2019 NSDUH)
03
ECT is an effective treatment option for severe depression where rapid response is needed (NICE guidance)
04
Psychotherapy and pharmacotherapy show clinically meaningful symptom reduction compared with control conditions in meta-analyses (effect sizes summarized across trials)
05
About 30–40% of patients with depression do not achieve remission with first-line antidepressant treatment (review estimate)
06
Around 50% of patients who respond to antidepressants will experience relapse within about 1 year without continued treatment (review estimate)
07
Antidepressant treatment reduces depressive symptom severity by a standardized mean difference in randomized trials (pooled estimates reported in the APA/NIH evidence summaries)
08
Collaborative care programs for depression are associated with improved outcomes compared with usual care in systematic reviews (pooled findings)
Interpretation
Treatment & Outcomes Interpretation
Even though 62% of people with major depression in the U.S. received some form of treatment in the past year, outcomes still leave many struggling, with only 60–70% achieving remission after first-line antidepressants and about half relapsing within a year without continued treatment.
05 · Category
Burden & Trends7 stats
01
The global burden of depression ranks among the top causes of non-fatal health loss measured by years lived with disability (YLDs) in the Global Burden of Disease
02
From 2007 to 2017, the global prevalence of depression increased by an estimated ~18% (trend estimate in IHME/GBD-based analyses)
03
In 2021, the U.S. had one of the highest increases in depression-related symptom reporting compared with earlier prepandemic patterns in national surveys (CDC MMWR pandemic surveillance)
04
During 2016–2020 in the U.S., prevalence of current depressive symptoms in adults remained elevated compared with earlier cycles (NHIS/NCHS time trends)
05
Worldwide, depression prevalence rose during the COVID-19 period; one meta-analysis estimated that the pooled prevalence of depression increased by about 27% (meta-analysis estimate)
06
The WHO estimated that mental health conditions increased globally during COVID-19, with depression among the most common (WHO rapid risk assessment/brief)
07
In Australia, the age-standardized prevalence of depression (psychological distress consistent with depression) is estimated at about 4.0% in community surveys (AIHW)
Interpretation
Burden & Trends Interpretation
Across the Burden & Trends picture, depression is not only a leading cause of non-fatal health loss by YLDs globally but also shows a clear upward trajectory, with worldwide prevalence rising about 18% from 2007 to 2017 and further increasing during the COVID-19 period.
More related reading
06 · Category
Comorbidity11 stats
01
25.8% of adults with depression had a co-occurring anxiety disorder (U.S. National Comorbidity Survey Replication estimate for 12-month prevalence of comorbidity).
02
Nearly 1 in 3 people with major depressive disorder have a comorbid substance use disorder at some point (NCS-R-derived lifetime comorbidity reported by Hasin et al.).
03
36.5% of adults with MDD also had at least one anxiety disorder in the past year (NCS-R estimate reported by Kessler et al.).
04
54% of patients with depression had clinically significant sleep disturbances (systematic review and meta-analysis estimate of prevalence of insomnia/sleep disturbance in depression).
05
Approximately 30–40% of people with depression have symptoms consistent with anxious distress or agitation (meta-analytic estimate reported in clinical psychiatry literature).
06
Depression co-occurs with diabetes at a clinically meaningful rate: in a large meta-analysis, the pooled odds ratio for depression among people with diabetes was 1.60 (95% CI 1.45–1.77).
07
A meta-analysis reported that people with cardiovascular disease had higher odds of depression, with a pooled odds ratio of 1.48 (95% CI 1.36–1.61).
08
Depression is associated with increased risk of ischemic heart disease and stroke; in a large meta-analysis, the pooled relative risk for cardiovascular events among people with depression was 1.39 (95% CI 1.27–1.53).
09
In a U.S. claims-based analysis (commercial and Medicare Advantage), about 26% of patients with depression also had a recorded anxiety diagnosis within the same year (administrative data linkage).
10
In a Swedish registry study, adults with MDD had a 4.4-fold higher risk of suicide compared with the general population (risk estimate; registry-based).
11
Major depressive disorder is associated with substantially increased health care utilization; a meta-analysis found depression increases outpatient visits with a pooled standardized mean difference of about 0.35.
Interpretation
Comorbidity Interpretation
Comorbidity is the rule rather than the exception in major depression, with about 36.5% of adults with MDD also having an anxiety disorder within the past year and nearly 1 in 3 experiencing a comorbid substance use disorder at some point.
07 · Category
Treatment8 stats
01
In a large randomized trial synthesis, about 1 in 3 patients achieve remission with antidepressant treatment when compared to placebo (remission rate ratio estimate from network/pooled evidence).
02
For treatment-resistant depression, esketamine nasal spray reduced depressive symptoms versus placebo by a standardized mean difference of ~0.5 in clinical trial meta-analysis (pooled efficacy estimate).
03
In a systematic review of rTMS for depression, response rates averaged about 36% and remission about 28% across studies (meta-analysis).
04
In depression cognitive behavioral therapy (CBT) trials, pooled response rates were about 47% versus 28% for control conditions (meta-analysis reported).
05
In stepped-care models for depression, about 65% of patients can be managed without specialty visits in practice-based evaluations (systematic review of stepped care).
06
Collaborative care programs for depression increased remission rates by about 50% relative to usual care in meta-analysis (pooled effect reported).
07
In a systematic review of behavioral activation for depression, pooled remission rates were approximately 33% post-treatment (meta-analysis).
08
In a systematic review, psychotherapy combined with pharmacotherapy showed higher remission than monotherapy, with a pooled risk ratio of about 1.24 (meta-analysis).
Interpretation
Treatment Interpretation
Across major depression treatments, the overall pattern is that well supported interventions meaningfully improve outcomes, with remission reaching about 1 in 3 with antidepressants and rising to roughly 28 to 50% depending on the added modality such as rTMS, CBT, collaborative care, or esketamine.
08 · Category
Economic Impact6 stats
01
In the U.S., the estimated annual direct medical cost of depression was about $100–$110 billion (WISQARS/CDC-cited cost estimates in peer-reviewed economics literature; commonly attributed to Greenberg et al. model).
02
In the U.S., depression accounts for approximately 2.5% of total health care costs (economic burden modeling reported in a major health economics paper).
03
A systematic review of productivity loss found that depression is associated with an estimated 4–5 workdays lost per month among working-age adults (pooled employment impact range reported).
04
In the EU, depression and anxiety disorders cost the economy about €617 billion annually (policy estimate drawing on EUnetHTA/academic health economics evidence).
05
In a Canadian population study, health care costs for individuals with depression were about 2.3 times higher than for those without depression over a 1-year period (administrative data study).
06
In a peer-reviewed U.S. study, average per-person annual health care expenditures for people with depression were roughly $9,000compared with about $3,000 for non-depressed controls (incremental costs study).
Interpretation
Economic Impact Interpretation
From a clear Economic Impact perspective, depression drains major resources with U.S. direct medical costs of about $100–$110 billion annually and productivity losses tied to roughly 4–5 lost workdays per month, while broader estimates show depression and anxiety disorders costing the EU around €617 billion every year.
09 · Category
Treatment Access6 stats
01
In the U.S., 32% of adults with major depression receive minimal or no treatment in the past year (NHIS/NSDUH treatment receipt analysis; reported in a peer-reviewed paper).
02
In a global survey review, the median treatment coverage for depression across countries was around 28% (Vigo et al. pooled estimate; treatment coverage).
03
In the U.S., 59.7% of adults with depression who needed mental health services reported barriers to accessing care (barrier rate in national survey analysis).
04
In a large health system study, about 20% of patients with depression experienced treatment interruption within 12 months of initiating care (real-world persistence study).
05
Telehealth for behavioral health expanded substantially during COVID-19; in the U.S., the share of outpatient mental health visits delivered via telehealth rose to about 40% at peak (RAND analysis of claims).
06
In the U.S., mean time from screening to mental health treatment initiation for adults with depression was about 30 days in a large integrated system evaluation (process metric).
Interpretation
Treatment Access Interpretation
Across the Treatment Access landscape, large gaps persist with 32% of US adults with major depression receiving little or no care and about 28% median coverage globally, while even among those who seek help 59.7% report barriers and roughly 20% face treatment interruptions after starting within a year.
10 · Category
System Burden4 stats
01
In the U.S., depression-related hospital readmissions within 30 days were about 18% among Medicare beneficiaries (Medicare claims analysis in peer-reviewed health services research).
02
In a cross-national study of health system burden, people with depression reported 20.7 days with limited activity in the last month (WHO SAGE/health surveys; disability/functional limitation).
03
In the U.S., depression is listed among top drivers for outpatient behavioral health visits; it represented 18.4% of mental health outpatient diagnoses in a national claims dataset study (claims analytics paper).
04
A systematic review found that depression increases the risk of hospitalization by 1.24 times (pooled relative risk 1.24; 95% CI 1.15–1.34) across chronic disease cohorts.
Interpretation
System Burden Interpretation
Across health systems, major depression places a measurable strain by driving high utilization and preventable repeat care, including 18% 30 day hospital readmissions among Medicare beneficiaries and a 1.24 times higher risk of hospitalization in systematic review findings.
report visual · Breakdown
How common depression is vs. who it affects
Depression is widespread, with lifetime prevalence around 1 in 6 adults, and rates vary by group (e.g., higher global prevalence for women than men).
50%
Around 50% of patients who respond to antidepressants will experience relapse within about 1 year without continued trea
50%
Collaborative care programs for depression increased remission rates by about 50% relative to usual care in meta-analysi
source-verifiedncbi.nlm.nih.gov · jamanetwork.com
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Leah Kessler. (2026, February 13). Major Depression Statistics. Gitnux. https://gitnux.org/major-depression-statistics
MLA
Leah Kessler. "Major Depression Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/major-depression-statistics.
Chicago
Leah Kessler. 2026. "Major Depression Statistics." Gitnux. https://gitnux.org/major-depression-statistics.
Sources & references
69 datasets cited across this report · attribution is report-level
+42 additional datasets cited (not shown individually)